Progen starts PI-88 HCC Phase II

Progen (ASX:PGL; PGLAF) began a Phase II trial in Taiwan comparing two doses of its PI-88 to no treatment following primary tumor resection in about 340 hepatocellular carcinoma (HCC) patients. The pr...